| Patel, Amar |
NCT03816254: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, With Cetuximab in Subjects With Advanced Solid Cancers |
|
|
| Not yet recruiting | 1 | 140 | NA | CC-95251, Cetuximab | Celgene | Neoplasms | 04/22 | 11/23 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Recruiting | N/A | 500 | US | VIA Disc NP | VIVEX Biologics, Inc., Moxie Clinical | Discogenic Pain, Back Pain, Back Pain, Low | 01/27 | 01/27 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 06/24 | 06/28 | | |
| Thourani, Vinod |
PACES, NCT04045665: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG |
|
|
| Recruiting | 3 | 3200 | Europe, Canada, US | Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy | Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center | Atrial Fibrillation, Stroke, Bleeding | 06/25 | 06/25 | | |
NCT02732691: JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study |
|
|
| Active, not recruiting | N/A | 68 | Europe, US, RoW | JenaValve Pericardial TAVR System | JenaValve Technology, Inc. | Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction | 05/19 | 04/24 | | |
| Terminated | N/A | 12 | US | Edwards Cardioband System, Transcatheter mitral valve repair (TMVr), Guideline Directed Medical Therapy | Edwards Lifesciences | Functional Mitral Regurgitation, Mitral Regurgitation, Mitral Insufficiency | 07/19 | 09/22 | | |
NCT03539458: Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification |
|
|
| Active, not recruiting | N/A | 11 | US | Tendyne Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Annular Calcification, Mitral Annulus Calcification, Cardiovascular Diseases, Valve Heart Disease, Heart Valve Diseases, Heart Valve Calcification, Mitral Valve Disease | 11/19 | 10/24 | | |
NCT02732704: THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study |
|
|
| Active, not recruiting | N/A | 100 | Europe, US | JenaValve Pericardial TAVR System | JenaValve Technology, Inc. | Aortic Regurgitation | 08/22 | 09/27 | | |
| Active, not recruiting | N/A | 180 | US | JenaValve Trilogy Heart Valve System | JenaValve Technology, Inc. | Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease | 08/23 | 08/28 | | |
| Active, not recruiting | N/A | 25 | Canada, US | HARPOON™ Beating Heart Mitral Valve Repair System | Edwards Lifesciences | Mitral Regurgitation | 10/23 | 12/27 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Recruiting | N/A | 15 | US | Transcatheter Tricuspid Valve Replacement | Trisol Medical | Tricuspid Regurgitation | 01/25 | 07/27 | | |
| Not yet recruiting | N/A | 1400 | US | Decision Aid, Shared Decision Making Skills Training | Massachusetts General Hospital, University of California, San Francisco, University of Colorado, Denver, University of North Carolina, Chapel Hill, Piedmont Healthcare, Providence Health & Services, University of Texas, Emory University, Patient-Centered Outcomes Research Institute | Aortic Stenosis | 05/27 | 10/27 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 06/24 | 06/28 | | |
| Recruiting | N/A | 30 | Canada, US | Cephea Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation | 06/24 | 06/29 | | |
| Recruiting | N/A | 1070 | Europe, US | Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure | 06/24 | 12/29 | | |
NCT05913908: EFS of the DUO System for Tricuspid Regurgitation (TANDEM II) |
|
|
| Recruiting | N/A | 15 | US | DUO Transcatheter Tricuspid Coaptation Valve System, DUO System | CroiValve Limited | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases | 04/25 | 10/29 | | |
| Recruiting | N/A | 870 | Canada, US | Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease | 12/24 | 03/29 | | |
NCT03382457: Clinical Study of Edwards Cardioband Tricuspid Valve Reconstruction System |
|
|
| Active, not recruiting | N/A | 55 | US | Transcatheter Tricuspid Valve Reconstruction, Edwards Cardioband Tricuspid Valve Reconstruction | Edwards Lifesciences | Tricuspid Regurgitation | 01/25 | 01/30 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
PRIMARY, NCT05051033: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds |
|
|
| Recruiting | N/A | 450 | Europe, Canada, US | Mitral valve repair, Mitral valve surgery, Transcatheter edge-to-edge repair, TEER | Annetine Gelijns, National Heart, Lung, and Blood Institute (NHLBI) | Mitral Valve Regurgitation | 01/28 | 01/32 | | |
| Active, not recruiting | N/A | 500 | Canada, US | MITRIS RESILIA Mitral Valve, Model 11400M | Edwards Lifesciences | Mitral Stenosis, Mitral Valve Insufficiency | 01/28 | 12/35 | | |
| Recruiting | N/A | 6500 | Europe, Canada, US | AtriClip LAA Exclusion System | AtriCure, Inc., Population Health Research Institute | Ischemic Stroke, Systemic Embolism | 12/31 | 04/32 | | |
| Fernandez, Kristen |
NCT04596683: Same-Day Discharge After Nipple-sparing Mastectomy or Skin-sparing Mastectomy With Breast Reconstruction |
|
|
| Recruiting | N/A | 60 | US | Same-day NSM or SSM | Georgetown University | Breast Cancer, Mastectomy; Lymphedema, Same Day Surgery, Nipple-sparing Mastectomy, Skin-sparing Mastectomy | 02/21 | 02/22 | | |
| Suspended | N/A | 2500 | US, RoW | Treatment Recommendation Surveys | PreludeDx, University of South Florida | DCIS | 11/25 | 11/35 | | |
| Farha, Maen |
| Suspended | N/A | 2500 | US, RoW | Treatment Recommendation Surveys | PreludeDx, University of South Florida | DCIS | 11/25 | 11/35 | | |
NCT03561454: A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients |
|
|
| Active, not recruiting | N/A | 100 | US | IORT | MedStar Franklin Square Medical Center, Medstar Health Research Institute | Early Stage Breast Cancer | 08/28 | 08/29 | | |
| Coordinator, Site |
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon |
|
|
| Completed | 4 | 30 | US | CREON, Pancrelipase | AbbVie | Cystic Fibrosis, Chronic Pancreatitis | 07/23 | 08/23 | | |
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections |
|
|
| Completed | 4 | 73 | Europe, RoW | BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine | AbbVie | Facial Corrections, Facial Lines | 10/23 | 10/23 | | |
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder |
|
|
| Completed | 4 | 19 | US | Oxybutynin, Gelnique | AbbVie | Overactive Detrusor, Neurogenic Bladder | 08/23 | 10/23 | | |
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines |
|
|
| Recruiting | 4 | 100 | Canada, US | BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA | AbbVie | Upper Facial Lines | 12/24 | 04/25 | | |
NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
|
|
| Recruiting | 4 | 336 | Canada, US, RoW | Risankizumab, Deucravacitinib | AbbVie | Moderate Plaque Psoriasis | 03/25 | 03/26 | | |
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis |
|
|
| Recruiting | 4 | 200 | US | Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab | AbbVie | Genital Psoriasis, Scalp Psoriasis | 09/24 | 10/25 | | |
| Active, not recruiting | 4 | 461 | Europe, Canada, Japan, RoW | Upadacitinib, RINVOQ, ABT-494 | AbbVie, AbbVie Inc. | Atopic Dermatitis | 07/24 | 08/24 | | |
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy |
|
|
| Active, not recruiting | 3 | 112 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine | AbbVie, Roche-Genentech | Acute Myeloid Leukemia (AML) | 09/22 | 04/25 | | |
NCT04994535: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence |
|
|
| Completed | 3 | 426 | Europe, Canada, US | OnabotulinumtoxinA, BOTOX, Placebo | Allergan | Platysma Prominence | 06/23 | 06/23 | | |
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles |
|
|
| Active, not recruiting | 3 | 1321 | Canada, US | MR-100A-01, Transdermal contraceptive delivery system | Mylan Technologies Inc., Mylan Inc. | Contraception | 01/25 | 01/25 | | |
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
|
|
| Completed | 3 | 199 | Europe, US, RoW | Dalbavancin single dose, Dalbavancin two dose, Comparator | AbbVie | Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections | 12/23 | 12/23 | | |
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants |
|
|
| Active, not recruiting | 3 | 140 | RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Forehead Lines | 09/24 | 09/24 | | |
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
|
|
| Recruiting | 3 | 1080 | Europe, US, RoW | Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine | Genmab, AbbVie | Follicular Lymphoma (FL) | 05/37 | 05/37 | | |
| Active, not recruiting | 3 | 429 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo | AbbVie | Giant Cell Arteritis (GCA) | 02/24 | 03/25 | | |
|
|
|
|
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Active, not recruiting | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 08/24 | 08/24 | | |
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 3 | 880 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Dupilumab | AbbVie, AbbVie Inc. | Atopic Dermatitis | 03/24 | 07/24 | | |
| Recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
|
|
| Recruiting | 3 | 450 | US | Ubrogepant, UBRELVY, Placebo for Ubrogepant | AbbVie | Migraine | 09/27 | 09/27 | | |
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab |
|
|
| Recruiting | 3 | 300 | US | Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B | AbbVie | Atopic Dermatitis | 08/25 | 03/26 | | |
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 3 | 1280 | US | Lutikizumab, ABT-981, Placebo | AbbVie | Hidradenitis Suppurativa | 12/26 | 12/26 | | |
| Active, not recruiting | 3 | 775 | Europe, Canada, US, RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Episodic Migraine | 11/24 | 11/24 | | |
|
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis |
|
|
| Active, not recruiting | 3 | 295 | Europe, Canada, Japan, US, RoW | Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT) | AbbVie | Myelofibrosis (MF) | 11/24 | 01/25 | | |
|
|
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis |
|
|
| Not yet recruiting | 3 | 80 | US | Mesalamine, Delzicol, Placebo | AbbVie | Ulcerative Colitis (UC) | 07/26 | 07/26 | | |
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) |
|
|
| Completed | 3 | 438 | Europe, Canada, US, RoW | Linaclotide 72 μg (FC Participants), Placebo (FC Participants), Linaclotide 145 μg (IBS-C Participants), Linaclotide 290 μg (IBS-C Participants) | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation, Irritable Bowel Syndrome With Constipation | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 132 | Europe, Canada, Japan, US | Risankizumab, SKYRIZI, ABBV-066, Ustekinumab | AbbVie | Psoriasis | 02/24 | 12/24 | | |
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD |
|
|
| Recruiting | 3 | 152 | US | Cariprazine, VRAYLAR, AGN-241780, Placebo | AbbVie | Autism Spectrum Disorder | 10/24 | 11/24 | | |
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation |
|
|
| Recruiting | 3 | 116 | Europe, US | Linaclotide, Placebo for Linaclotide | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | 08/25 | 11/25 | | |
NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain |
|
|
| Recruiting | 3 | 800 | US | Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive | AbbVie | Endometriosis | 12/24 | 06/30 | | |
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
|
|
| Recruiting | 3 | 75 | US | Atogepant, QULIPTA | AbbVie | Chronic Migraine | 12/24 | 04/25 | | |
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants |
|
|
| Active, not recruiting | 3 | 159 | US | VOLITE XC, JUVÉDERM® VOLITE™ XC | AbbVie | Neck Lines | 10/24 | 10/24 | | |
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada | HArmonyCa Lidocaine Injectable Gel | Allergan | Mid Face Volume Deficit | 05/25 | 05/25 | | |
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata |
|
|
| Recruiting | 3 | 1500 | Europe, Canada, Japan, US, RoW | Upadacitinib, Rinvoq, ABT-494, Placebo | AbbVie | Alopecia Areata | 05/25 | 01/28 | | |
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | Telisotuzumab Vedotin, ABBV-399, Docetaxel | AbbVie | Non Small Cell Lung Cancer | 06/25 | 03/28 | | |
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars |
|
|
| Recruiting | 3 | 156 | Europe, Canada | ELAPR002f Injectable Gel, Saline Control | AbbVie | Atrophic Acne Scars | 08/25 | 08/25 | | |
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder |
|
|
| Recruiting | 3 | 280 | US | Cariprazine Flexible Dose | AbbVie | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 09/25 | 09/25 | | |
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Active, not recruiting | 3 | 515 | Europe, US, RoW | Bimatoprost (SR) | AbbVie | Open-Angle Glaucoma, Ocular Hypertension | 08/25 | 08/25 | | |
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma |
|
|
| Recruiting | 3 | 65 | US, RoW | XEN45 (Glaucoma Gel Stent) | AbbVie | Open-Angle Glaucoma | 08/25 | 08/25 | | |
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis |
|
|
| Recruiting | 3 | 480 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo | AbbVie | Rheumatoid Arthritis | 09/25 | 08/26 | | |
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy |
|
|
| Recruiting | 3 | 1328 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Placebo | AbbVie | Hidradenitis Suppurativa | 11/25 | 08/27 | | |
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. |
|
|
| Active, not recruiting | 3 | 265 | Europe, Canada, Japan, US, RoW | Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199 | AbbVie, Roche-Genentech | Multiple Myeloma | 08/26 | 08/26 | | |
|
NCT06063967: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. |
|
|
| Recruiting | 3 | 276 | Europe, Canada, Japan, US, RoW | Risankizumab SC, ABBV-066, SKYRIZI, Placebo for risankizumab | AbbVie | Crohn's Disease | 03/26 | 02/28 | | |
NCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) |
|
|
| Recruiting | 3 | 1059 | US | Ubrogepant, Ubrelvy, Placebo-Matching Ubrogepant | AbbVie | Migraine | 05/26 | 05/26 | | |
TEMPLE, NCT05748483: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine |
|
|
| Recruiting | 3 | 520 | Europe, Canada, RoW | Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate | AbbVie | Migraine | 06/26 | 06/26 | | |
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) |
|
|
| Recruiting | 3 | 16 | US | Paricalcitol | AbbVie | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | 06/26 | 10/26 | | |
NCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab |
|
|
| Recruiting | 3 | 40 | Europe, US | Adalimumab, Risankizumab, ABBV-066, Skyrizi | AbbVie | Juvenile Psoriatic Arthritis | 09/26 | 10/28 | | |
SELECT-SLE, NCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ, Placebo | AbbVie | Systemic Lupus Erythematosus | 10/26 | 10/27 | | |
VIALE-T, NCT04161885 / 2019-002621-30: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) |
|
|
| Active, not recruiting | 3 | 424 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, VENCLEXTA, Azacitidine, Best Supportive Care (BSC) | AbbVie | Acute Myeloid Leukemia (AML), Cancer | 11/26 | 11/26 | | |
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
|
|
| Recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/27 | 12/29 | | |
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. |
|
|
| Recruiting | 3 | 90 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ, ABT-494, Tocilizumab | AbbVie | Juvenile Idiopathic Arthritis | 02/27 | 06/29 | | |
NCT05711394: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant | AbbVie | Episodic Migraine | 03/28 | 05/28 | | |
NCT05782907: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. |
|
|
| Recruiting | 3 | 110 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ | AbbVie | Ulcerative Colitis | 08/28 | 10/33 | | |
NCT05995353: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 3 | 110 | Europe, US, RoW | Risankizumab, ABBV-066, SKYRIZI | AbbVie | Crohn's Disease | 04/29 | 04/29 | | |
NCT05707949: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine |
|
|
| Enrolling by invitation | 3 | 250 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689 | AbbVie | Episodic Migraine | 11/29 | 11/29 | | |
EPCORE FL-1, NCT05409066 / 2021-000169-34: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma |
|
|
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Epcoritamab, GEN3013, Rituximab, Lenalidomide | Genmab, AbbVie | Follicular Lymphoma (FL) | 11/29 | 06/30 | | |
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2/3 | 840 | Japan, US, RoW | Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | AbbVie | Non-Small Cell Lung Cancer | 10/31 | 10/31 | | |
NCT06345339: A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants |
|
|
| Recruiting | 2/3 | 2800 | US | Armour Thyroid, AGN-282176, Levothyroxine, Synthetic T4 | AbbVie | Hypothyroidism | 06/28 | 06/28 | | |
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2/3 | 660 | Europe, US, RoW | Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab | AbbVie | Hepatocellular Carcinoma | 09/30 | 09/30 | | |
NCT04853368 / 2020-005805-25: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis |
|
|
| Terminated | 2 | 48 | Europe, US, RoW | ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119 | AbbVie | Cystic Fibrosis (CF) | 06/23 | 06/23 | | |
|
AIM-CD, NCT05068284: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease |
|
|
| Terminated | 2 | 176 | Europe, Canada, Japan, US, RoW | ABBV-154, Placebo | AbbVie | Crohn's Disease | 07/23 | 07/23 | | |
|
NCT03339128 / 2017-003770-14: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children |
|
|
| Recruiting | 2 | 95 | Europe, Canada, US | Eluxadoline, Viberzi, Placebo | AbbVie | Irritable Bowel Syndrome | 12/26 | 12/26 | | |
NCT06151535: A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants |
|
|
| Recruiting | 2 | 30 | Europe | ELAPR002f Injectable Gel | AbbVie | Skin Quality Deficit | 01/25 | 01/25 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
NCT06241846: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC |
|
|
| Recruiting | 2 | 100 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 02/27 | 02/29 | | |
NCT06257875: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 200 | Japan, US | Lutikizumab Matching Placebo, Adalimumab Matching Placebo, Lutikizumab, ABT-981, Adalimumab, Humira | AbbVie | Ulcerative Colitis | 04/27 | 04/27 | | |
NCT05760313: A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide |
|
|
| Recruiting | 2 | 30 | Europe, US, RoW | Linaclotide, Linzess, Placebo | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation | 09/25 | 09/25 | | |
NCT05141006: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) |
|
|
| Active, not recruiting | 2 | 83 | Canada, US | BOTOX, OnabotulinumtoxinA, Botulinum Toxin Type A, Placebo for BOTOX | Allergan | Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | 07/24 | 02/25 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
NCT05771428: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease |
|
|
| Active, not recruiting | 2 | 240 | Europe, Japan, US, RoW | ABBV-552, Placebo for ABBV-552 | AbbVie | Alzheimer's Disease (AD) | 08/24 | 09/24 | | |
NCT05216250: Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor |
|
|
| Active, not recruiting | 2 | 174 | Canada, US | BOTOX, Botulinum Toxin Type A, Placebo for BOTOX | AbbVie | Upper Limb Essential Tremor (UL ET) | 11/24 | 06/25 | | |
EAISE, NCT04309474 / 2019-003753-29: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke |
|
|
| Active, not recruiting | 2 | 121 | Europe, Canada, Japan, US, RoW | Elezanumab, ABT-555, Placebo | AbbVie | Acute Ischemic Stroke | 04/24 | 12/24 | | |
NCT06032546: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 |
|
|
| Recruiting | 2 | 140 | Europe, Canada, Japan, US, RoW | Budigalimab, ABBV-181, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382 | AbbVie | Human Immuno-deficiency Virus (HIV) Disease | 04/25 | 10/26 | | |
